MX2022013236A - Tratamiento de la obesidad hipotalamica. - Google Patents

Tratamiento de la obesidad hipotalamica.

Info

Publication number
MX2022013236A
MX2022013236A MX2022013236A MX2022013236A MX2022013236A MX 2022013236 A MX2022013236 A MX 2022013236A MX 2022013236 A MX2022013236 A MX 2022013236A MX 2022013236 A MX2022013236 A MX 2022013236A MX 2022013236 A MX2022013236 A MX 2022013236A
Authority
MX
Mexico
Prior art keywords
treatment
hypothalamic obesity
disclosure relates
hypothalamic
obesity
Prior art date
Application number
MX2022013236A
Other languages
English (en)
Inventor
Jørgen Drejer
Kim Krogsgaard
Berit Edsberg
Original Assignee
Saniona As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona As filed Critical Saniona As
Publication of MX2022013236A publication Critical patent/MX2022013236A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se relaciona con el tratamiento de la Obesidad Hipotalámica con Tesofensina sola o en combinación con un bloqueador beta. En particular la descripción se relaciona con tratamientos que conducen a la pérdida de peso, pérdida de masa grasa, en particular grasa visceral y la reducción de síntomas de la prediabetes en pacientes que padecen de Obesidad Hipotalámica.
MX2022013236A 2020-04-22 2021-04-22 Tratamiento de la obesidad hipotalamica. MX2022013236A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170952 2020-04-22
EP20209186 2020-11-23
PCT/EP2021/060548 WO2021214233A1 (en) 2020-04-22 2021-04-22 Treatment of hypothalamic obesity

Publications (1)

Publication Number Publication Date
MX2022013236A true MX2022013236A (es) 2023-01-24

Family

ID=75562770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013236A MX2022013236A (es) 2020-04-22 2021-04-22 Tratamiento de la obesidad hipotalamica.

Country Status (6)

Country Link
US (1) US20260115180A1 (es)
EP (1) EP4138830A1 (es)
JP (1) JP7784144B2 (es)
CA (1) CA3176183A1 (es)
MX (1) MX2022013236A (es)
WO (1) WO2021214233A1 (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA971525B (en) 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1589957A1 (en) 2003-02-05 2005-11-02 IPCA Laboratories Limited Pharmaceutical compositions and process of production thereof
DE102005034351A1 (de) 2005-07-22 2007-01-25 Sension, Biologische Detektions- Und Schnelltestsysteme Gmbh Farb-Umschlag-Indikator zur Statusanzeige von RFID-Tickets und -Etiketten
US20070053983A1 (en) 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
US8815285B2 (en) 2006-03-28 2014-08-26 Wockhardt Ltd. Extended release dosage forms of metoprolol
WO2008012346A1 (en) 2006-07-28 2008-01-31 Farmaprojects, S. A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
US8235632B2 (en) 2010-05-14 2012-08-07 Illinois Tool Works Inc. Cargo bag valve deflector
WO2012052834A2 (en) 2010-10-21 2012-04-26 Inventia Healthcare Private Limited Multiple unit particulate system comprising metoprolol succinate
KR101708538B1 (ko) 2011-08-26 2017-02-20 욱크하르트 리미티드 심혈관 질환의 치료 방법
CA2858522A1 (en) 2011-12-09 2013-06-13 Wockhardt Limited Methods for treating cardiovascular disorder
EA029543B1 (ru) * 2012-02-16 2018-04-30 Саниона А/С Способ лечения, профилактики или уменьшения сердечно-сосудистых побочных эффектов тезофенсина
EP2846792B1 (en) * 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
US20160143864A1 (en) 2013-07-09 2016-05-26 Sun Pharmaceutical Industries Limited Extended-release pharmaceutical compositions of metoprolol
HUE055974T2 (hu) * 2015-03-03 2022-01-28 Saniona As Tesofensine és metoprolol kombinációs készítmény
US20190060301A1 (en) * 2016-01-15 2019-02-28 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
WO2020144146A1 (en) * 2019-01-07 2020-07-16 Saniona A/S Tesofensine for reduction of body weight in prader-willi patients

Also Published As

Publication number Publication date
US20260115180A1 (en) 2026-04-30
JP2023523738A (ja) 2023-06-07
JP7784144B2 (ja) 2025-12-11
CA3176183A1 (en) 2021-10-28
WO2021214233A1 (en) 2021-10-28
EP4138830A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
EP3447491A3 (en) Diagnosis and treatments relating to th2 inhibition
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
NZ598709A (en) Treating acute decompensated heart failure with relaxin
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
NO20056252L (no) Terapeutiske og profylaktiske metoder for neuromuskulaere lidelser
WO2011011642A3 (en) Biphasic and dynamic adjustable support devices and methods with assist and recoil capabilities for treatment of cardiac pathologies
EA033415B1 (ru) Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
MX382400B (es) Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea.
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
EP4327873A3 (en) Tpp1 formulations and methods for treating cln2 disease
TR201203732T1 (tr) Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX390722B (es) Tratamiento de resistencia a diureticos.
WO2010093993A3 (en) Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
ZA202203367B (en) Treatment of menstrual cycle-induced symptoms
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
EA200801310A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
WO2010127096A3 (en) Novel therapeutic treatments using centhaquin
MX2022000835A (es) Metodos para tratar la esclerosis multiple.
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
TW200730169A (en) Use of a β-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints
WO2009088849A3 (en) Treatment or prevention of inflammation by targeting cyclin d1